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Background: This study forms part of the first complete characterization of the dose–response curve for glycopyrrolate
(GP) delivered using Co-Suspension™ Delivery Technology via a metered dose inhaler (MDI). We examined the lower
GP MDI dose range to determine an optimal dose for patients with moderate-to-severe chronic obstructive pulmonary
disease (COPD).
Methods: This randomized, double-blind, chronic-dosing, balanced incomplete-block, placebo-controlled, crossover
study compared six doses of GP MDI (18, 9, 4.6, 2.4, 1.2, and 0.6 μg, twice daily [BID]) with placebo MDI BID and open-
label tiotropium dry powder inhaler (18 μg, once daily [QD]) in patients with moderate-to-severe COPD. Patients were
randomized into 1 of 120 treatment sequences. Each sequence included 4 of 8 treatments administered for 14-day
periods separated by 7- to 21-day washout periods.
The primary efficacy endpoint was change from baseline in forced expiratory volume in 1 s area under the curve from
0 to 12 h (FEV1 AUC0–12) on Day 14. Secondary efficacy endpoints included peak change from baseline (post-dose) in
FEV1 and inspiratory capacity (IC) on Days 1, 7, and 14; change from baseline in morning pre-dose trough FEV1 on
Days 7 and 14; change from baseline in 12-h post-dose trough FEV1 on Day 14; time to onset of action (≥10 %
improvement in mean FEV1) and the proportion of patients achieving ≥12 % improvement in FEV1 on Day 1;
and pre-dose trough IC on Days 7 and 14. Safety and tolerability were also assessed.
Results: GP MDI 18, 9, 4.6, and 2.4 μg demonstrated statistically significant and clinically relevant increases in FEV1
AUC0–12 compared with placebo MDI following 14 days of treatment (modified intent-to-treat population = 120).
GP MDI 18 μg was non-inferior to open-label tiotropium for peak change in FEV1 on Day 1 and morning pre-dose
trough FEV1 on Day 14. All doses of GP MDI were well tolerated with no unexpected safety findings.
Conclusions: These efficacy and safety results support GP MDI 18 μg BID as the most appropriate dose for evaluation
in Phase III trials in patients with moderate-to-severe COPD.
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Symptomatic chronic obstructive pulmonary disease
(COPD) is often treated in a step-wise manner, with guide-
lines recommending the initiation of maintenance therapy
with a long-acting bronchodilator, either a long-acting
β2-agonist (LABA) or a long-acting muscarinic antagonist
(LAMA) [1]. Patients who remain symptomatic require
addition of a second long-acting bronchodilator or an in-
haled corticosteroid (ICS) through a combination of inhalers.
The properties associated with different inhalers
may make some devices more suitable for certain pa-
tient groups than others. For example, pressurized
metered dose inhalers (MDIs) are currently the most
commonly used devices overall for respiratory drug
delivery [2] and can be used by patients with severe
airflow limitation who may struggle to activate a dry
powder inhaler (DPI) [3, 4]. At the time when this
study was performed, licensed LAMA and LAMA/
LABA fixed-dose combination (FDC) therapies in
COPD were only available via DPIs or a Soft Mist™
Inhaler (Respimat®). There is therefore an opportunity
to widen the choice of inhalers available to patients
by developing MDIs that can deliver a LAMA as
monotherapy as well as in combination with other
agents, such as a LABA and/or an ICS.
The requirement for chlorofluorocarbon-free propellant
formulated MDIs has proved challenging for the creation
of stable formulations and has led to the development of
innovative technological advances to overcome these bar-
riers. Co-Suspension™ Delivery Technology has evolved
such that drug particles can be suspended in hydrofluor-
oalkane (HFA) propellant by the use of spray-dried porous
particles of distearoyl-phosphatidylcholine. These particles
form strong non-specific associations with the drug mole-
cules, preventing the drugs from interacting with each
other in the suspension and providing long-term stability.
In analytical studies, these Co-Suspension delivery tech-
nology formulations have demonstrated excellent stability
and dose uniformity, even in the nanogram dose range,
with one, two, and three active ingredients formulated in a
single inhaler [5].The clinical study reported here is one of a number of
studies in a Phase II program that assessed the safety and
efficacy of a single-agent LAMA (glycopyrrolate [GP]) MDI,
a single-agent LABA (formoterol fumarate [FF]) MDI, and
dual LAMA/LABA (GP/FF [GFF]) FDC MDI, all delivered
using Co-Suspension delivery technology (NCT00871182 [6],
NCT01350128 [7], NCT01085045 [8], NCT01587079 [9],
and NCT01349868 [10]). The LAMA, GP, delivered using
Co-Suspension delivery technology as GP MDI, has demon-
strated bronchodilator effects across a dose range of 4.6–
36 μg in patients with COPD (NCT01350128 [7]). However,
to confirm the optimum dose of GP MDI, there is a require-
ment to further characterize the dose–response relationship
below GP MDI 4.6 μg. This study is the first assessment of
the lower end of the dose–response curve for GP MDI.
This is a randomized, double-blind, chronic-dosing,
placebo-controlled, multicenter crossover study to estab-
lish the dose–response curve for the GP MDI (18, 9, 4.6,
2.4, 1.2, and 0.6 μg administered twice daily [BID])
monotherapy. The aim is to provide additional support
for the selection of the optimal dose of GP MDI to carry
forward in studies investigating the LAMA/LABA MDI
FDC in patients with COPD.
Methods
Patients
Male and female patients of 40–80 years of age with a
diagnosis of COPD as defined by the American Thoracic
Society (ATS) [11] and a smoking history of at least 10
pack-years were included in the study. Key lung function
criteria for inclusion were pre- and post-short-acting
bronchodilator (ipratropium bromide; Atrovent® HFA)
forced expiratory volume in 1 s (FEV1)/forced vital cap-
acity (FVC) ratio <0.7, post-bronchodilator FEV1 ≥30 %
and <80 % of the predicted value and ≥750 mL at screen-
ing (Visit 1), and a pre-bronchodilator FEV1 <80 % at
randomization (Visit 2) calculated using the Third National
Health and Nutrition Examination Survey (NHANES III)
reference equations [12]. Key exclusion criteria were diag-
nosis of asthma, α1-antitrypsin deficiency, or any other
respiratory disease. Poorly controlled COPD that had
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costeroids within 3 months or antibiotics within 6 weeks
prior to screening (Visit 1) also led to exclusion. In
addition, patients with clinically significant abnormal elec-
trocardiogram (ECG) results; pregnant or lactating women;
and patients who could not meet ATS criteria for accept-
able spirometry results were excluded [13].
Patients using oral β-agonists, inhaled LABAs, LABA/
ICS combination inhalers, phosphodiesterase inhibitors,
mast cell stabilizers, leukotriene antagonists, or tiotro-
pium, discontinued these for the duration of the trial
and instead received open-label ipratropium four times
daily during the run-in period. Patients using ICS/LABA
FDC inhalers who had received a stable dose for at least
4 weeks prior to screening were switched to the corre-
sponding dose of a single ICS agent, such as fluticasone,
mometasone or budesonide administered BID for the re-
mainder of the study. Patients receiving a maintenance
dose of an ICS that was not administered as a FDC were
permitted to continue, provided they had been main-
tained on a stable dose for at least 4 weeks prior to
screening.
Other prohibited medications included non-selective β-
receptor antagonists, tricyclic antidepressants, monoamine
oxidase inhibitors, anticonvulsants, and phenothiazines.
Study design and treatment
This was a randomized, incomplete-block, crossover,
placebo- (blinded) and active- (open-label) control study
(NCT01566773), conducted at 10 sites in the USA from
11 April 2012 to 10 August 2012. Six doses of GP MDI
(18, 9, 4.6, 2.4, 1.2, and 0.6 μg), administered BID for
14 days, were assessed. Investigators and patients were
blinded to GP MDI and placebo MDI treatment using
non-distinguishable MDIs. Open-label tiotropium
(18 μg; Spiriva® HandiHaler®) DPI administered once
daily (QD) was included as an active control.Fig. 1 Study design schematic. Rand Randomization; PFT Pulmonary FunctIn this study, GP is expressed as the salt, glycopyrro-
late (glycopyrronium bromide), where a dose of 18 μg is
equivalent to 14.4 μg glycopyrronium (active moiety).
Following screening, patients were randomized using an
interactive web response system to one of 120 pre-defined
treatment sequences, comprising four out of the eight
possible treatments. Each treatment period was 14 days,
separated by a 7- to 21-day washout period (Fig. 1).
At each study visit and prior to performing any study
procedures, patients had to confirm that they had with-
held all COPD medication for at least 6 h, or the visit
was rescheduled as soon as practical and within the spe-
cified visit windows. During the study, albuterol sulfate
(salbutamol HFA; Ventolin®) MDI was permitted as
needed for relief of symptoms. During screening and
washouts between treatment periods, ipratropium brom-
ide (Atrovent® HFA) MDI was used as maintenance
medication.
This study was conducted in accordance with Inter-
national Conference on Harmonization guidelines, the
Declaration of Helsinki [14], and the US Code of Federal
Regulations.Assessments
Patients attended scheduled clinic visits at screening
(Visit 1), randomization (Visit 2), then on Days 1, 7, and
14 of each treatment period.
All pulmonary function tests, including FEV1, FVC
and inspiratory capacity (IC) as defined in ATS guide-
lines, were performed in accordance with ATS criteria
[13]. Spirometry was performed to assess lung function
pre- and post-dose at each study visit. The assessed time
points on Days 1 and 7 of each treatment period were
60 and 30 min pre-dose and 15, 30, 60, and 120 min
post-dose. On Day 14, post-dose time points were
assessed up to 12 h post-dose.ion Test; Rx Treatment
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pressure, and ECGs, conducted at every clinic visit.
Blood samples were taken pre- and post-dose on Days 1
and 14 of each treatment period to perform laboratory
assessments including hematology and blood chemistry.
Adverse events (AEs) and serious AEs were documented
by investigators, with paradoxical bronchospasm and dry
mouth classified as events of interest.
Endpoints
The primary objective of this study was to assess efficacy
relative to placebo MDI of GP MDI. To this end, each
dose of GP MDI was compared with placebo MDI on
the primary efficacy endpoint; FEV1 area under the
curve from 0 to 12 h (AUC0–12) relative to baseline on
Day 14 of each treatment period. FEV1 AUC0–12 values
were normalized by dividing by the length of time over
which they were obtained (typically 12 h). The key sec-
ondary endpoints were time to onset of action (≥10 %
improvement from baseline in FEV1) on Day 1; peak
change from baseline in FEV1 on Days 1, 7, and 14;
change from baseline in morning pre-dose trough FEV1Fig. 2 Patient disposition figure. Patients were randomized into 1 of 120 tr
possible treatments administered for 14-day periods separated by 7- to 21-on Days 7 and 14; change from baseline in 12-h post-
dose trough FEV1 on Day 14; peak change from baseline
in IC on Days 1, 7, and 14; mean change from baseline
in morning pre-dose trough IC on Days 7 and 14; and
the proportion of patients achieving ≥12 % improvement
in FEV1 on Day 1.
Statistical analysis
The planned sample size was 120 patients, designed to
provide approximately 93 % power to detect differences
of 100 mL in FEV1 AUC0–12. The 100-mL difference was
selected on the grounds that it is the minimum clinically
important difference, defined as the change in FEV1 that
can be perceived by the patient [15]. The principal popu-
lation for primary efficacy analyses was the modified
intent-to-treat (mITT) population, comprising all pa-
tients who completed at least two treatment periods
with at least 2 h of post-dose data for Day 14 from both
periods. For the primary efficacy analysis of assessing the
dose–response curve, the family-wise Type I error was
not controlled for multiplicity beyond specifying a pri-
mary endpoint and the six key comparisons, namelyeatment sequences. Each sequence included four out of the eight
day washout periods. GP glycopyrrolate; MDI metered dose inhaler
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compare each dose of GP MDI with placebo MDI, a lin-
ear mixed-effects model was used with FEV1 AUC0–12 as
the dependent variable, and baseline trough FEV1, bron-
chodilator reversibility, period, sequence, and treatment
as covariates. Baseline was defined as the mean of
pre-dose values obtained from the first day of each treat-
ment cycle averaged across periods.
Secondary efficacy analysis for the primary efficacy
endpoint assessed the non-inferiority of each treatment
group to open-label tiotropium using a margin for clin-
ical relevance of 100 mL. Other secondary efficacy ana-
lyses involved superiority comparisons of secondary
endpoints for each treatment group versus placebo MDI
and non-inferiority comparisons versus open-label
tiotropium. Non-inferiority was only determined for a
treatment group if the lower bound of the 95 % confi-
dence interval (CI) for the difference was above
−100 mL and if all higher dose levels were statistically
significantly non-inferior to open-label tiotropium. Non-
inferiority testing was not performed for time to onset ofTable 1 Patient demographics and characteristics (ITT/safety popula
Parameter GP MDI
18 μg
n = 64
9 μg
n = 64
4.6 μg
n = 62
2.4
n =
Age, years
Mean (SD) 61.6 (8.1) 60.6 (8.6) 60.8 (8.5) 60.
Gender, n (%)
Male 30 (46.9) 33 (51.6) 29 (46.8) 34
Race, n (%)
White 58 (90.6) 58 (90.6) 57 (91.9) 58
Smoking status, n (%)
Current 37 (57.8) 35 (54.7) 42 (67.7) 37
Duration of COPD, years
Mean (SD) 7.2 (7.3) 6.0 (6.1) 8.0 (7.7) 6.6
Total CAT score
Mean (SD) 20.0 (6.7) 20.7 (6.4) 19.5 (6.0) 19.
na 59 59 61 60
Mean FEV1, % predicted (SD)
a
Pre-bronchodilator 47.0 (11.9) 46.6 (13.0) 47.0 (11.3) 46.
Post-bronchodilator 55.2 (12.6) 53.7 (12.7) 54.2 (11.7) 55.
Change from pre- to
post-bronchodilator
19.2 (16.9) 17.9 (17.2) 16.8 (14.4) 21.
Mean FEV1, L (SD)
a
Pre-bronchodilator 1.363 (0.392) 1.395 (0.490) 1.409 (0.432) 1.4
Post-bronchodilator 1.603 (0.432) 1.601 (0.472) 1.632 (0.493) 1.6
Change from pre- to
post-bronchodilator
0.239 (0.199) 0.206 (0.203) 0.224 (0.183) 0.2
amITT population; bn = 55
CAT COPD Assessment Test; COPD chronic obstructive pulmonary disease; FEV1 forc
dose inhaler; mITT modified intent-to-treat; SD standard deviationaction on Day 1, for which cumulative incidence
Kaplan–Meier curves were plotted. The proportion of
patients achieving ≥12 % improvement from baseline on
Day 1 was tabulated and a logistic regression was used
to compare treatments.
For safety analyses the safety population was used, de-
fined as all patients who were randomized and received at
least one dose of study treatment and had a post-baseline
safety assessment for that treatment. Safety and tolerability
data, including laboratory parameters, vital signs and ECG
results were summarized descriptively, with AEs tabulated
according to severity, relationship to study drug and the
Medical Dictionary for Regulatory Activities system level
and preferred term.
Results
Patient disposition and baseline characteristics
Overall, 140 patients were randomly assigned to treat-
ment groups, and 110 (79 %) patients completed four
treatment periods with 120 included in the mITT popu-
lation (Fig. 2). A total of 30 patients withdrew from thetion)
Placebo
n = 62
Open-label
tiotropium
n = 62
μg
64
1.2 μg
n = 57
0.6 μg
n = 59
2 (9.0) 61.6 (7.9) 60.3 (8.9) 61.3 (8.3) 60.7 (7.1)
(53.1) 34 (59.6) 33 (55.9) 33 (53.2) 33 (53.2)
(90.6) 53 (93.0) 55 (93.2) 56 (90.3) 57 (91.9)
(57.8) 34 (59.6) 40 (67.8) 40 (64.5) 40 (64.5)
(6.0) 6.7 (7.5) 7.5 (5.9) 8.3 (7.7) 7.2 (5.3)
8 (6.7) 20.5 (7.3) 19.9 (6.3) 20.3 (6.4) 20.5 (6.5)
55 56 60 57
4 (11.7) 46.2 (10.6) 45.8 (11.9) 45.6 (11.6) 43.4 (10.9)
1 (11.5) 54.5 (12.1) 52.9 (11.9) 53.1 (12.7) 52.5 (11.7)
0 (15.8) 18.9 (15.3) 17.5 (16.4) 18.0 (16.6) 22.5 (15.2)b
08 (0.466) 1.369 (0.366) 1.384 (0.456) 1.358 (0.417) 1.313 (0.416)
70 (0.484) 1.609 (0.400) 1.602 (0.478) 1.587 (0.486) 1.585 (0.450)
61 (0.170) 0.240 (0.181) 0.218 (0.225) 0.229 (0.216) 0.272 (0.162)b
ed expiratory volume in 1 s; GP glycopyrrolate; ITT intent-to-treat; MDI metered
Fig. 3 Primary endpoint: LSM change from baseline in FEV1 AUC0–12 on Day 14 (mITT population). Primary efficacy comparison for superiority to
placebo: *p < 0.05; **p < 0.001; ***p < 0.0001. FEV1 AUC0–12 forced expiratory volume in 1 s, area under the curve from 0 to 12 h; GP glycopyrrolate;
LSM least squares mean; MDI metered dose inhaler; mITT modified intent-to-treat
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continuation (Fig. 2). There were no clinically relevant
differences in smoking status, disease duration, or airway
limitation between the treatment groups. Overall, the
majority of patients were current smokers (61 %) with a
mean COPD duration of 7 years (Table 1). Airway re-
versibility at baseline ranged from 0.272 L (open-label
tiotropium) to 0.206 L (GP MDI 9 μg [Table 1]).Efficacy analyses
All GP MDI doses (except 0.6 μg) showed a similar-shaped
profile for FEV1 improvement over time on Day 14, with an
early onset of action and peak treatment effect within 1–2
h post-dose (See Additional file 1: Figure S1).
Least squares mean (LSM) change from baseline in
FEV1 AUC0–12 on Day 14 ranged from 64 mL with
GP MDI 0.6 μg to 159 mL with GP MDI 18 μg
(Fig. 3, Table 2). All doses of GP MDI demonstrated
statistically significant increases in FEV1 AUC0–12 on
Day 14 compared with placebo MDI (all p < 0.05),
with clinically relevant differences versus placebo
MDI for GP 18, 9, 4.6, and 2.4 μg (LSM difference
158, 126, 141, and 126 mL, respectively; p < 0.0001;
see Additional file 1: Figure S2). Open-label tiotropium
demonstrated a statistically and clinically significant in-
crease versus placebo MDI in FEV1 AUC0–12 on Day 14
(LSM difference, 224 mL; p < 0.0001). No dose of GP MDI
demonstrated non-inferiority to open-label tiotropium
with the lower bound of the 95 % CI exceeding theclinically relevant difference of −100 mL in FEV1 AUC0–12
on Day 14 (see Additional file 1: Figure S2).
For time to onset of action (≥10 % improvement in
mean FEV1) on Day 1 (Fig. 4), all doses of GP MDI ex-
cept 0.6 μg demonstrated a significantly faster onset of
action compared with placebo MDI. The proportion of
patients who had achieved onset of action by 15 min
post-dose ranged from 7 % with GP MDI 0.6 μg to 30 %
with GP MDI 9 μg (29 % with GP MDI 18 μg), and 39 %
for open-label tiotropium, compared with 4 % for pla-
cebo MDI.
Table 2 shows the secondary endpoints on Day 1
and Day 14 across the GP MDI dose range 0.6–18 μg
BID. GP MDI 18 μg was superior to placebo MDI for
all secondary endpoints except for change in morning
pre-dose trough FEV1 on Day 7 (data not shown).
Treatment differences for GP MDI 18 μg versus pla-
cebo MDI were above the pre-defined threshold of
100 mL for peak change from baseline in FEV1 on
Days 1, 7, and 14. GP MDI 9, 4.6, and 2.4 μg were
often significantly superior to placebo MDI with re-
gard to changes in lung function parameters; however,
significance was less common for GP MDI 1.2 μg
and, particularly, 0.6 μg versus placebo MDI.
GP MDI 18 μg consistently showed superior improve-
ments in lung function compared with the lower doses
of GP MDI, but there was no clear dose–response
amongst the lower doses for many of the secondary end-
points (Table 2). GP MDI 18 and 9 μg were non-inferior
to open-label tiotropium for peak change from baseline
Table 2 Spirometry endpoints: Day 1 and Day 14 (mITT population)
GP MDI Placebo Open-label
tiotropium18 μg 9 μg 4.6 μg 2.4 μg 1.2 μg 0.6 μg
Primary endpoint: change from baseline in FEV1 AUC0–12, mL: Day 14
n 58 58 59 60 53 54 52 55
LSM 159† 127† 143† 127† 97*** 64* 1 225†
95 % CI 116, 202 84, 170 100, 185 85, 169 52, 141 20, 108 −43, 46 182, 269
Change from baseline in morning pre-dose trough FEV1, mL: Day 14
n 58 59 60 59 55 55 56 57
LSM 89*** 80*** 67** 77** 68** 29 −8 126†
95 % CI 47, 132 38, 122 26, 109 35, 118 25, 111 −14, 72 −50, 35 84, 168
Change from baseline in evening 12-h post-dose trough FEV1, mL: Day 14
n 58 58 59 60 53 55 54 56
LSM 116† 69* 99*** 112† 66* 55 1 164†
95 % CI 69, 163 22, 117 52, 145 65, 158 17, 115 7, 104 −48, 49 116, 211
Change from baseline in morning pre-dose trough inspiratory capacity, mL: Day 14
n 58 59 60 60 55 54 56 56
LSM 94* 45 64 104* 69 34 9 138**
95 % CI 32, 156 −16, 106 3, 124 43, 165 6, 132 −30, 97 −54, 71 76, 201
Peak change from baseline in FEV1, mL: Day 1
n 59 59 60 59 55 55 60 57
LSM 231† 226† 165† 170† 136** 107 57 270†
95 % CI 191, 272 186, 267 125, 205 130, 211 95, 177 65, 149 17, 97 229, 311
Peak change from baseline in FEV1, mL: Day 14
n 58 59 60 60 54 54 54 57
LSM 288† 288† 287† 261† 246*** 188 130 361†
95 % CI 236, 339 237, 340 236, 338 210, 312 193, 299 135, 241 77, 183 309, 413
Peak change from baseline in inspiratory capacity, mL: Day 1
n 59 59 61 60 55 54 60 56
LSM 234*** 263† 151 183* 126 82 80 343†
95 % CI 163, 304 193, 333 82, 219 113, 252 54, 198 9, 155 10, 150 271, 414
Peak change from baseline in inspiratory capacity, mL: Day 14
n 58 59 60 60 54 54 56 56
LSM 280† 259*** 288† 226** 261*** 172 77 284†
95 % CI 197, 363 177, 341 206, 370 145, 308 176, 346 87, 256 −6, 161 200, 368
Adjusted difference versus placebo: *p < 0.05; **p < 0.01; ***p < 0.001; †p < 0.0001
AUC0–12 area under the curve from 0 to 12 h; CI confidence interval; FEV1 forced expiratory volume in 1 s; GP glycopyrrolate; LSM least squares mean; MDI
metered dose inhaler; mITT modified intent-to-treat
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7 and 14. GP MDI 18 and 9 μg were non-inferior to
open-label tiotropium for change from baseline in
morning pre-dose trough FEV1, using the pre-specified
margin of 100 mL, on Days 7 and 14. For the propor-
tion of patients achieving ≥12 % improvement in FEV1
on Day 1 (Fig. 5), a dose–response was seen, with the
exception of GP MDI 4.6 μg, with a nominally higher
percentage of patients achieving ≥12 % improvementwith GP MDI 18 μg compared with doses below
4.6 μg, and with GP MDI 9 μg compared with GP
MDI 1.2 and 0.6 μg (all p < 0.05).
Safety and tolerability
A total of 54.3 % (76/140) of patients reported a
treatment-emergent AE (TEAE). The incidence of
TEAEs was similar across the different doses of GP
MDI, ranging from 22.0 % of patients with GP MDI
Fabbri et al. Respiratory Research  (2016) 17:109 Page 8 of 110.6 μg to 29.7 % with GP MDI 2.4 μg, and compared
with 24.2 % and 25.8 % in placebo MDI and open-label
tiotropium groups, respectively (Table 3). Dry mouth
(3.1–9.7 %), back pain, cough, and hypertension (all
<5 %) were the most commonly reported AEs (Table 4),
with AEs for all GP MDI doses comparable to those re-
ported for placebo MDI and open-label tiotropium
groups. A total of five patients reported serious AEs that
led to study discontinuation, including one patient in
each of GP MDI 9, 2.4, and 0.6 μg, placebo MDI, and
open-label tiotropium treatment arms (Table 3). All
events were considered unrelated to treatment. No im-
portant trends were observed in clinical laboratory
results, vital signs, and ECGs.
Discussion
The results of this study identified GP 18 μg as the opti-
mal dose that demonstrated the greatest efficacy versus
placebo MDI with no accompanying increase in AEs.
These results enabled the selection of GP 18 μg BID as
the most appropriate dose of GP, formulated using
Co-Suspension delivery technology delivered via MDI, to
take forward into Phase III clinical trials. As Co-
Suspension delivery technology enables uniform and reli-
able delivery of very low doses of GP via the MDI device
[5], this study is the first to have characterized the actual
dose–response curve of GP using a sub-microgram dose,
which previously could not be formulated either as a MDIFig. 4 Time to onset of action (≥10 % improvement from baseline FEV1) o
difference versus placebo: *p < 0.05; **p < 0.01; ***p < 0.001; ****p≤ 0.0001.
†††p < 0.001; ††††p≤ 0.0001. Time to onset was defined as the first post-bas
baseline FEV1, where baseline was defined as the mean of evaluable 60- an
obtained using the Murray method to account for correlation between the
FEV1 forced expiratory volume in 1 s; GP glycopyrrolate; MDI metered doseor a DPI. GP MDI 18 μg was generally the most effective
dose versus placebo MDI, with a clear dose response from
0.6 μg to 4.6 μg, followed by a relatively flat dose–response
curve at the higher doses.
The primary endpoint for this study was FEV1
AUC0–12 at Day 14 relative to baseline. While this
represents the full efficacy profile for GP MDI, this
endpoint only represents the first half of the efficacy
profile for tiotropium DPI, where the magnitude of
effect in the second 12 h has been shown to be
smaller [16–20]. Nonetheless, non-inferiority was de-
fined as a lower 95 % CI bound ≥−100 mL relative to
open-label tiotropium for the primary endpoint, FEV1
AUC0–12 at Day 14 relative to baseline. The value of
100 mL was selected based on ATS/European Re-
spiratory Society task force recommendations and
studies that suggest this is the minimum difference
required for clinical relevance, defined as the smallest
difference in FEV1 that is perceived by patients as
important [15, 21]. For the primary endpoint, a dose–
response was observed across GP MDI doses, with
GP MDI 18 μg demonstrating the largest benefit
(158 mL), with even the lower bound of the 95 % CI
(107 mL, 208 mL) exceeding the minimum clinically
important difference. Despite this robust and clinically
meaningful finding, no dose of GP MDI was statisti-
cally non-inferior to open-label tiotropium for the
primary endpoint on Day 14.n Day 1 (mITT population). Cumulative data are shown. Adjusted
Adjusted difference versus open-label tiotropium: †p < 0.05; ††p < 0.01;
eline time when a ≥10 % improvement in FEV1 was seen relative to
d 30-min pre-dose values across Visits 2, 5, 8, and 11. P-values were
times to onset observed in the same subject at different periods.
inhaler; mITT modified intent-to-treat
Fig. 5 Proportion of patients achieving ≥12 % improvement in FEV1 on Day 1 (mITT population). Treatment difference versus placebo: *p < 0.05;
**p < 0.01; ***p < 0.0001. Treatment difference versus open-label tiotropium: †p < 0.01; ††p < 0.001; †††p < 0.0001. Estimated percentages, differences
between percentages, and p-values were based on a logistic regression model with achievement of ≥12 % improvement in FEV1 as binary
response and the following factors in the model: baseline FEV1, bronchodilator reversibility at Screening, period, and treatment. Exchangeable
correlation between responses of the same subject at different periods was assumed. FEV1 forced expiratory volume in 1 s; GP glycopyrrolate;
MDI metered dose inhaler; mITT modified intent-to-treat
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tiotropium, with a response versus placebo MDI for the
primary endpoint of 224 mL, compared with 107 and
199 mL observed in Phase III studies at Week 12 and
Week 6, respectively [17, 20]. Whilst a peak FEV1 of ap-
proximately 360 mL was observed for open-label tiotro-
pium on Days 7 and 14 of this trial, previous studies
have reported lower values for this endpoint, ranging
from 240 to 280 mL [22, 23]. Perhaps noteworthy with
respect to the large tiotropium response was that the
tiotropium group in this study also demonstrated the
largest airway reversibility at baseline.Table 3 Overview of TEAEs (safety population)
GP MDI
18 μg
n = 64
9 μg
n = 64
4.6 μg
n = 62
2.4 μg
n = 64
At least one TEAE
n (%) 17 (26.6) 18 (28.1) 14 (22.6) 19 (29.7)
TEAEs related to study treatment
n (%) 5 (7.8) 4 (6.3) 4 (6.5) 6 (9.4)
Serious AEs
n (%) 0 1 (1.6) 0 1 (1.6)
TEAEs leading to study withdrawal
n (%) 3 (4.7) 2 (3.1) 0 1 (1.6)
AE adverse event, GP glycopyrrolate, MDI metered dose inhaler, TEAE treatment-emGP MDI 18 μg consistently demonstrated superior-
ity to placebo MDI for the secondary efficacy end-
points. GP MDI showed an early onset of action, with
a peak effect 1–2 h post-dose, followed by a gradual
decrease in effect over 12 h, supporting the use of
BID dosing. Night-time and early-morning symptoms
have been reported as a common occurrence in pa-
tients with COPD [24, 25], with sleep disturbance
linked to poorer outcomes including high exacerba-
tion frequency and poor survival [26, 27]. Broncho-
dilator efficacy is therefore required in the second
half of the 24-h dosing period, and further studies arePlacebo
n = 62
Open-label
tiotropium
n = 62
1.2 μg
n = 57
0.6 μg
n = 59
14 (24.6) 13 (22.0) 15 (24.2) 16 (25.8)
4 (7.0) 2 (3.4) 5 (8.1) 3 (4.8)
0 1 (1.7) 1 (1.6) 1 (1.6)
1 (1.8) 1 (1.7) 1 (1.6) 1 (1.6)
ergent adverse event
Table 4 TEAEs reported for ≥3 % of patients in a treatment group (safety population)
n (%) GP MDI Placebo
n = 62
Open-label
tiotropium
n = 62
18 μg
n = 64
9 μg
n = 64
4.6 μg
n = 62
2.4 μg
n = 64
1.2 μg
n = 57
0.6 μg
n = 59
Dry mouth 2 (3.1) 3 (4.7) 3 (4.8) 6 (9.4) 3 (5.3) 4 (6.8) 3 (4.8) 6 (9.7)
Back pain 0 2 (3.1) 0 2 (3.1) 2 (3.5) 0 1 (1.6) 0
Cough 0 2 (3.1) 0 1 (1.6) 0 1 (1.7) 3 (4.8) 0
Hypertension 1 (1.6) 1 (1.6) 1 (1.6) 2 (3.1) 1 (1.8) 1 (1.7) 1 (1.6) 1 (1.6)
Peripheral edema 0 0 2 (3.2) 0 0 1 (1.7) 2 (3.2) 0
Sinusitis 1 (1.6) 0 0 2 (3.1) 1 (1.8) 0 0 1 (1.6)
Muscle spasm 0 1 (1.6) 0 1 (1.6) 0 2 (3.4) 0 0
Pain in extremity 0 0 1 (1.6) 0 0 2 (3.4) 1 (1.6) 0
Excoriation 0 1 (1.6) 2 (3.2) 1 (1.6) 0 0 0 0
Nasopharyngitis 1 (1.6) 0 0 0 0 0 2 (3.2) 0
GP glycopyrrolate; MDI metered dose inhaler; TEAE treatment-emergent adverse event
Fabbri et al. Respiratory Research  (2016) 17:109 Page 10 of 11required to investigate the benefits conferred by BID
delivery of GP MDI through a second peak of broncho-
dilation in the evening, in particular versus tiotropium
QD where the magnitude of effect in the second 12 h has
been shown to be smaller [16–20].
Conclusions
In conclusion, in this dose-ranging study evaluating
single-agent GP MDI formulated using Co-Suspension
delivery technology at doses of 0.6–18 μg, GP 18 μg
demonstrated a robust and clinically relevant benefit
compared with placebo MDI and is the most appropriate
dose of GP MDI BID to take forward into Phase III clin-
ical trials.
Additional file
Additional file 1: Figure S1. Adjusted change from baseline in FEV1
over time on Day 14 (mITT population). Figure S2. LSM difference in FEV1
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